HIMS
Hims & Hers Health, Inc.
NYSE · Healthcare · Medical - Equipment & Services · US
$27.40
+6.61%Oct 30, 2026, 17:10 UTC
Law Offices of Frank R. Cruz announced a class action lawsuit against Hims & Hers Health, Inc. on behalf of investors who acquired its securities from August 4, 2025, to July 29, 2026.
Source:Oct 29, 2026, 22:46 UTC
Hims & Hers Health closed at $29.69, up 1.24% from the previous trading day.
Source:Oct 23, 2026, 22:45 UTC
Hims & Hers Health shares closed at $27.71, down 4.87% from the previous trading session.
Source:Oct 23, 2026, 17:26 UTC
Hims & Hers Health, Inc. urged a court to dismiss a consumer deception lawsuit concerning its data privacy disclosures, subscription charges, and cancellation policies.
Source:Oct 21, 2026, 12:22 UTC
Hims & Hers Health, Inc. launched a subcutaneous injection intended to increase testosterone, administered twice weekly.
Source:Oct 20, 2026, 18:49 UTC
Hims & Hers Health, Inc. shares rose 5% on Tuesday.
Source:Oct 20, 2026, 00:08 UTC
Law Offices of Howard G. Smith announced a securities class action alleging that Hims & Hers Health, Inc. failed to disclose key facts to investors during the period from August 4, 2025, through July 29, 2026.
Source:Oct 12, 2026, 20:05 UTC
Hims & Hers Health announced that it will report third-quarter 2026 financial results after market close on November 9, 2026, and host a conference call at 5:00 p.m. ET that day.
Source:Oct 7, 2026, 20:24 UTC
Hims & Hers Health appointed Jonathan M. Franklin as chief accounting officer effective October 5, 2026, and as principal accounting officer effective October 9, 2026; Irene Becklund resigned as principal accounting officer effective October 9, 2026.
Source:Oct 2, 2026, 21:45 UTC
Bayer announced plans to invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio, expected to create about 600 jobs with the first module operational in 2031.
Sep 23, 2026, 12:30 UTC
The U.S. Federal Trade Commission filed a lawsuit alleging that telehealth company Hims & Hers used deceptive practices, including disclosing customers' health data, enrolling them in hard-to-cancel subscriptions, and bypassing real-time doctor consultations.
Sep 22, 2026, 19:00 UTC
MAHA Center, a nonprofit tied to HHS Secretary Robert F. Kennedy Jr., solicited corporate sponsorship payments of up to $300,000 for the Sept. 29 MAHA Summit in exchange for access to top U.S. health officials including Kennedy and CMS head Mehmet Oz.
Source:Aug 24, 2026, 16:45 UTC
Hims & Hers Health received a warning from Visa due to excessive customer disputes over its weight-loss drug subscription service, leading to its inclusion in Visa's Acquirer Monitoring Program (VAMP).
Aug 11, 2026, 13:45 UTC
Hims & Hers Health announced plans to enter the peptide market within the year to capture demand in the rapidly growing healthcare market.
Source:Jul 24, 2026, 03:40 UTC
An FDA advisory panel voted to recommend easing restrictions on four peptides (BPC-157, KPV, TB-500, MOTS-C), potentially expanding the market for telehealth firms like Hims & Hers Health.
Jul 17, 2026, 20:17 UTC
Hims & Hers Health announced that Chief Accounting Officer Irene Becklund will depart the company effective October 9, 2026.
Source:Jul 8, 2026, 12:34 UTC
Hims & Hers Health acquired Eucalyptus for $1.15 billion, adding 850,000 customers and approximately $450 million of ARR across eight international markets.
Source:Jul 8, 2026, 12:34 UTC
Hims & Hers Health secured a $400 million receivables facility from JPMorgan to improve financial flexibility.
Source:Jul 1, 2026, 18:15 UTC
Hims & Hers Health shares surged 9% on Wednesday.
Source:Jul 1, 2026, 00:00 UTC
Hims & Hers Health, Inc. entered into a Master Receivables Purchase Agreement with JPMorgan Chase Bank, N.A., establishing a $400 million uncommitted facility for the purchase of eligible receivables, and amended its existing revolving credit agreement to permit this transaction.
Jun 4, 2026, 13:00 UTC
Hims & Hers Health appointed Dr. Anant Vinjamoori as Chief Medical Officer of the Hims brand.
Source:Jun 2, 2026, 09:00 UTC
Hims & Hers Health, Inc. completed its acquisition of Eucalyptus, the parent company of Juniper, expanding its weight management care in Germany.
May 21, 2026, 00:00 UTC
Hims & Hers Health, Inc. issued $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, comprising $350.0 million initial principal and a $52.5 million option to purchase additional notes, with conversion into Class A Common Stock at an initial rate of 33.8590 shares per $1,000 principal amount.